Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 29, 2015 1:27 PM ET

Biotechnology

Company Overview of Reata Pharmaceuticals, Inc.

Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs for difficult-to-treat diseases. The company develops drugs that target proteins involved in the cellular biology of oxidative stress, inflammation, and mitochondrial function to address the unmet medical needs of patients with serious or life threatening diseases. Its product pipeline comprises drugs under development for treating immuno-oncology and ophthalmology problems, cancers, Friedreich’s ataxia and mitochondrial myopathies, and cardiovascular problems. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The compa...

2801 Gateway Drive

Suite 150

Irving, TX 75063

United States

Founded in 2002

Phone:

972-865-2219

Fax:

800-998-3206

Key Executives for Reata Pharmaceuticals, Inc.

Chairman, Founding Chief Executive Officer and President
Age: 61
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Compensation as of Fiscal Year 2015.

Reata Pharmaceuticals, Inc. Key Developments

Reata Pharmaceuticals, Inc Receives FDA Clearance for its RTA 744 to Begin Clinical Development

Reata Pharmaceuticals announced that its lead development candidate, RTA 744, has received FDA clearance to begin clinical testing in patients with advanced brain cancers.

Reata Enrolls First Patient in the MOXIe Study

Reata announced enrollment of the first patient in a Phase 2 dose-ranging study examining the safety, tolerability, and efficacy of RTA 408 Oral Capsules versus placebo for the treatment of patients with Friedreich's ataxia. MOXIe (A two-part, randomized, placebo-controlled Phase 2/3 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia) is a multi-center study in approximately 52 patients and is designed to support a potential NDA submission. Part 1 of the study is a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of RTA 408 at 2.5 mg, 5 mg, and 10 mg in patients with Friedreich's ataxia. Part 2 of the study is a randomized, placebo-controlled, double-blind, parallel-group study to evaluate the safety, efficacy, and pharmacodynamics of up to 2 dose levels of RTA 408. The study is designed to evaluate a variety of clinical, and biochemical endpoints, including exercise capacity and quality of life measures.

Reata Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Reata Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Similar Private Companies By Industry

Company Name Region
PlasmaGenix, Inc. United States
Phylogix, Inc. United States
Polymerix Corporation United States
SelectX Pharmaceuticals, Inc. United States
Embryo Armor Technologies, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Reata Pharmaceuticals, Inc., please visit reatapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.